Eli Lilly and Company
PulseAugur coverage of Eli Lilly and Company — every cluster mentioning Eli Lilly and Company across labs, papers, and developer communities, ranked by signal.
10 day(s) with sentiment data
-
Insilico Medicine and SK Biopharmaceuticals ink $2.5B AI drug discovery deal
Insilico Medicine and SK Biopharmaceuticals have entered into a significant research collaboration valued at over $2.5 billion. The partnership will leverage Insilico's AI-driven Pharma.AI platform to discover novel dru…
-
Medicare to offer weight-loss drugs, straining doctor capacity
Starting next month, Medicare will offer weight-loss drugs like Wegovy and Zepbound for a subsidized price of $50 per month. This initiative is expected to lead to a significant surge in demand, potentially overwhelming…
-
GLP-1 Drugs Could Save Adults Hundreds of Thousands in Medical Costs
A new study from the National Bureau of Economic Research (NBER) suggests that middle-aged adults using GLP-1 drugs for obesity could save over $192,000 in lifetime medical costs. These savings are even higher for indiv…
-
Abridge raises $316M, partners with NVIDIA and Eli Lilly for AI in medicine
Abridge, a startup focused on ambient AI for healthcare, has announced a significant expansion of its platform and secured new strategic investments. The company's AI-native clinician intelligence platform now aims to m…
-
Google DeepMind spinoff Isomorphic Labs advances AI drug discovery
Isomorphic Labs, a Google DeepMind spinoff, is advancing AI-driven drug discovery by developing new computational systems. Their Isomorphic Drug Design Engine (IsoDDE) builds upon AlphaFold's protein structure predictio…
-
SpaceX eyes healthcare with Starlink, orbital drug manufacturing, and AI
SpaceX is exploring multiple avenues into the healthcare sector, leveraging its Starlink satellite internet service to improve remote healthcare access in underserved regions. The company also plans to manufacture pharm…
-
Miasma malware targets developers via compromised npm packages
A sophisticated malware campaign, dubbed Miasma by Microsoft, has targeted developers by compromising 32 npm packages under the `@redhat-cloud-services` umbrella. This attack plants backdoors in developer tools like Cla…
-
Eli Lilly launches direct-to-consumer drug sales bypassing PBMs
Eli Lilly has launched LillyDirect, a direct-to-consumer platform for its weight-loss medications like Zepbound, bypassing traditional pharmacy benefit managers (PBMs). This integrated system includes online physician r…
-
Medical breakthroughs extend lifespans, but cures remain elusive
Recent medical breakthroughs, particularly in cancer and obesity treatment, offer extended lifespans rather than outright cures. These advancements are the result of decades of sustained scientific investment and resear…
-
AI drug discovery firm Chai lands deals with Pfizer and Eli Lilly
Chai Discovery, an AI drug discovery startup, has secured significant partnerships with pharmaceutical giants Eli Lilly and Pfizer. The company's advanced antibody design models, including the recently deployed Chai-3, …
-
Eli Lilly pays $2.75B for AI-designed drugs from Insilico Medicine
Eli Lilly and Company has acquired drug candidates designed by Insilico Medicine for $2.75 billion. This significant investment highlights the growing role of artificial intelligence in pharmaceutical research and devel…
-
Weight loss drug coverage uncertain despite insurer formulary listings
Despite Eli Lilly's announcement that its obesity medications will be listed on the formularies of major pharmacy benefit managers, actual coverage remains uncertain. Many health insurers and plan sponsors are reluctant…
-
France to reimburse anti-obesity drugs for first time in EU
France is set to become the first European Union country to reimburse anti-obesity medications for severely obese patients starting mid-June. The government estimates this initiative will cost approximately €100 million…
-
Eli Lilly plans $4B vaccine company acquisitions; Quantinuum IPO planned
Eli Lilly is reportedly planning to acquire three vaccine development companies in a deal potentially worth nearly $4 billion. The acquisitions include Limmatech for up to $780 million, Vaccine Co for up to $1.55 billio…
-
AI in Healthcare: Experts Debate Trust, Data, and Integration Challenges
AI applications in healthcare are being discussed, with experts highlighting concerns about the reliability and trustworthiness of current models deployed in clinical settings. Panelists at the Imagination in Action eve…
-
Genesis AI partners with Incyte in $120M drug discovery deal
Genesis Molecular AI has secured a significant partnership with Incyte, a global biotech company, valued at $120 million. This deal includes $80 million in upfront cash and a $40 million equity investment, with potentia…
-
FDA approves first gene therapy for genetic deafness
The FDA has approved the first gene therapy designed to treat deafness caused by a specific genetic mutation. This groundbreaking treatment targets the OTOF gene, which is crucial for transmitting sound signals from the…
-
Eli Lilly invests $2.75B in AI-designed drugs from Insilico Medicine
Eli Lilly has acquired drug candidates designed by Insilico Medicine for $2.75 billion, highlighting AI's growing role in pharmaceutical discovery. This significant investment underscores a broader trend, with the pharm…
-
Pharma giants Eli Lilly and Nvidia partner to accelerate AI drug discovery
Eli Lilly and Company has partnered with Nvidia to develop a powerful supercomputer aimed at accelerating drug discovery using artificial intelligence. This collaboration, announced in October and expanded in January wi…
-
Eli Lilly raises full-year revenue forecast after Q1 sales jump 56%
DeepSeek has released a significant update to its AI models, marking a notable advancement for the company. This update comes as Eli Lilly reported a 56% year-over-year revenue increase for its first quarter, leading th…